# DCLK1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- DCLK1 encodes functionally distinct isoforms (DCLK1-L and DCLK1-S) regulated by alternative promoter usage (α and β promoters) and complex epigenetic mechanisms, including promoter methylation, which are critical for its roles in neurodevelopment and cancer stem cell maintenance.
- The protein possesses a dual domain architecture, featuring an N-terminal DCX domain for microtubule binding and a C-terminal serine/threonine kinase domain, enabling it to integrate cytoskeletal dynamics with signaling cascades.
- Aberrant activation of the β-promoter, often due to FOXD3 repression loss, drives DCLK1-S expression, which is a hallmark of cancer stem cells and is associated with poor prognosis and epithelial-mesenchymal transition (EMT) in numerous solid tumors.
- DCLK1's kinase activity modulates key oncogenic pathways including Wnt/β-catenin, Notch, Hippo-YAP, and NF-κB, and it is a critical regulator of EMT and cancer stem cell self-renewal, making it a therapeutic target for small-molecule inhibitors and monoclonal antibodies.
- Epigenetic alterations, particularly promoter methylation patterns, serve as diagnostic and prognostic biomarkers in cancers like lung and colorectal cancer, with DNA methyltransferase inhibitors showing potential to restore DCLK1-L expression.
- Beyond cancer, DCLK1 dysregulation is implicated in non-neoplastic diseases such as Parkinson's disease, atherosclerosis, and idiopathic pulmonary fibrosis, highlighting its broad biological significance and potential as a therapeutic target across multiple pathologies.

---

## Executive Summary & Key Metadata

Doublecortin-like kinase 1 (DCLK1) is a microtubule-associated serine/threonine kinase that has emerged as a critical regulator of neurodevelopment, intestinal tuft cell biology, and cancer stem cell (CSC) maintenance. The gene encodes multiple isoforms through alternative promoter usage and splicing, with distinct long (DCLK1-L) and short (DCLK1-S) variants exhibiting differential expression patterns in normal versus malignant tissues. DCLK1's dual functionality—combining a doublecortin (DCX) microtubule-binding domain with a kinase domain—positions it as a unique molecular integrator of cytoskeletal dynamics and phospho-signaling cascades. Clinically, DCLK1 overexpression correlates with poor prognosis across numerous solid tumors, and its expression marks tumor-initiating cells in the intestine, pancreas, and other organs. The gene is subject to complex epigenetic regulation, including promoter methylation and histone modifications, which are being actively explored as diagnostic biomarkers and therapeutic targets.

| Attribute | Detail |
|-----------|--------|
| **HGNC Symbol** | DCLK1 |
| **UniProt Accession** | O15075 |
| **Representative PDB ID** | True (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 13q13.3 (GRCh38: chr13:35,682,318-36,078,267) |
| **Primary Molecular Function** | Serine/threonine-protein kinase; microtubule polymerization and stabilization; neuronal migration; CSC self-renewal |
| **Disease & Pathology Associations** | Colorectal cancer, pancreatic ductal adenocarcinoma, gastric cancer, lung adenocarcinoma, renal cell carcinoma, bladder cancer, glioblastoma, Parkinson's disease, atherosclerosis, idiopathic pulmonary fibrosis, Hirschsprung's disease |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *DCLK1* gene is located on the long arm of chromosome 13 at cytogenetic band 13q13.3. The gene spans approximately 396 kilobases of genomic DNA, encompassing 22 exons that are variably utilized across different isoforms [1]. The genomic architecture is notable for its two distinct promoter regions: a canonical 5' promoter (α-promoter) and an intragenic promoter located within intron V (β-promoter) [2]. This dual-promoter organization enables tissue-specific and context-dependent expression of functionally divergent protein isoforms.

The α-promoter drives transcription of the full-length DCLK1-L isoform (isoform 1), which is predominantly expressed in normal tissues, particularly in the nervous system and quiescent intestinal epithelium. In contrast, the β-promoter, situated approximately 100 kb downstream, drives expression of the short isoform DCLK1-S (isoform 2), which lacks the N-terminal DCX domain and initiates translation at an internal methionine residue [3, 4]. The β-promoter is normally repressed in healthy colonic epithelium by the transcription factor FOXD3, but becomes aberrantly activated during colorectal carcinogenesis due to epigenetic silencing of FOXD3 [4, 5, 6].

### 1.2 Promoter Architecture and Transcription Factor Binding

The α-promoter region contains a canonical TATA box and multiple CpG islands that are subject to dynamic methylation. In normal tissues, this promoter is hypomethylated, permitting constitutive expression of DCLK1-L. During colon carcinogenesis, however, the α-promoter undergoes progressive hypermethylation, leading to transcriptional silencing of the long isoform [1, 2]. Quantitative methylation-specific PCR (qMSP) studies have demonstrated that DCLK1 promoter methylation is a frequent event in colorectal cancer, with methylation levels correlating with tumor stage and patient survival [1, 2].

The β-promoter, located within intron V, is regulated by distinct transcription factor networks. FOXD3 functions as a transcriptional repressor of this promoter in normal colonic cells, and its expression is lost in human colorectal cancers through promoter hypermethylation [4, 5, 6]. The loss of FOXD3-mediated repression results in aberrant DCLK1-S expression, which drives CSC phenotypes and epithelial-mesenchymal transition (EMT) [4]. Additionally, the β-promoter contains hypoxia-responsive elements, and hypoxic stimulation has been shown to induce alternative-promoter switching in clear cell renal cell carcinoma, favoring DCLK1-S expression and tumor malignancy [3].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation studies have identified several enhancer elements within the DCLK1 locus that interact with the α-promoter in neuronal tissues. These enhancers are bound by neurogenic transcription factors including NeuroD1, NeuroD2, and TBR1, which coordinate DCLK1 expression during cortical development [4]. In the intestine, the tuft cell-specific transcription factor POU2F3 has been shown to regulate DCLK1 expression, establishing a lineage-specific enhancer network [5, 6].

The three-dimensional chromatin architecture of the DCLK1 locus undergoes reorganization during cellular differentiation. In embryonic stem cells, the locus exists in a poised conformation with bivalent histone marks (H3K4me3 and H3K27me3). Upon commitment to neuronal or tuft cell lineages, the locus transitions to an active state characterized by H3K27ac deposition and loss of Polycomb-mediated repression [1, 4].

### 1.4 Alternative Splicing and Isoform Diversity

The DCLK1 gene produces multiple transcript variants through alternative splicing and promoter usage. The major isoforms include:

**DCLK1-L (Isoform 1):** The canonical full-length protein of 740 amino acids (~82 kDa) containing both the N-terminal DCX domain and the C-terminal serine/threonine kinase domain [2]. This isoform is expressed in post-mitotic neurons, where it regulates microtubule dynamics and neuronal migration [1, 2].

**DCLK1-S (Isoform 2):** A shorter variant of approximately 470 amino acids (~50 kDa) that lacks the DCX domain and initiates from the β-promoter [3, 4]. This isoform retains the kinase domain but lacks microtubule-binding capacity. DCLK1-S is specifically expressed in cancer stem cells and is associated with aggressive tumor phenotypes [2, 3, 4].

**Additional splice variants:** RNA sequencing studies have identified numerous additional splice variants, including isoforms with alternative C-terminal sequences and variants that skip specific exons [3, 4]. The expression of these variants is dynamically regulated by psychotropic drugs in the brain, suggesting activity-dependent alternative splicing [3]. In the developing mouse brain, DCLK1 isoforms exhibit distinct spatial and temporal expression patterns, with the long isoform predominating in embryonic neurogenesis and short isoforms appearing postnatally [4].

### 1.5 Regulation by Non-Coding RNAs

DCLK1 expression is extensively regulated by microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Multiple miRNAs directly target the DCLK1 3' untranslated region (UTR), including:

- **miR-15b:** Suppresses DCLK1 expression and enhances chemo/radiotherapy sensitivity in colorectal cancer [5]
- **miR-137:** Inhibits colon cancer stem cell tumorigenicity through DCLK1 targeting [6]
- **miR-195:** Suppresses pancreatic cancer progression by targeting DCLK1 [1]
- **miR-330-5p:** Mediates the effects of lncRNA SNHG1 on cisplatin resistance in NSCLC [2]
- **miR-424:** Inhibits neuroblastoma viability and invasion via DCLK1 targeting [3]
- **let-7e:** Attenuates oncogenic phenotypes in colorectal cancer cells [4]
- **let-7i:** Shed from bone mesenchymal stem cell extracellular vesicles, suppresses lung cancer via the KDM3A/DCLK1/FXYD3 axis [5]
- **miR-150-5p:** Downregulated in chronic sleep deprivation, leading to DCLK1 upregulation in Parkinson's disease [6]

LncRNAs that regulate DCLK1 include SNHG1, which functions as a competing endogenous RNA (ceRNA) to sponge miR-15b and miR-330-5p, thereby derepressing DCLK1 expression in gastric cancer and NSCLC [1, 2].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The DCLK1 protein exhibits a modular architecture that reflects its dual functions as both a microtubule-associated protein and a signaling kinase. From N-terminus to C-terminus, the protein comprises:

**N-terminal DCX Domain (Residues 1-140):** This domain is homologous to the doublecortin (DCX) protein and mediates microtubule binding. The DCX domain folds into a ubiquitin-like β-grasp fold with two tandem subdomains that create a positively charged groove capable of interacting with the acidic C-terminal tails of tubulin [2]. This domain is essential for microtubule polymerization and stabilization, and its deletion in DCLK1-S abolishes microtubule-binding activity.

**Serine/Threonine Kinase Domain (Residues 350-620):** The catalytic domain adopts the canonical bilobed kinase fold characteristic of the CAMK (calcium/calmodulin-dependent protein kinase) family. The N-lobe contains the glycine-rich ATP-binding loop (GxGxxG motif), while the C-lobe harbors the catalytic loop (HRDLKPEN) and the activation segment [2, 3]. The kinase domain exhibits constitutive activity, although autophosphorylation at specific residues modulates its catalytic efficiency.

**C-terminal Regulatory Region (Residues 620-740):** This region contains multiple phosphorylation sites and interaction motifs that mediate protein-protein interactions and subcellular localization. Notably, this region contains a calmodulin-binding domain that confers calcium/calmodulin sensitivity to the kinase activity [2].

### 2.2 Structural Insights from Crystallography

High-resolution crystal structures of the DCLK1 kinase domain have been solved in complex with various inhibitors, providing critical insights into the structural basis of kinase regulation and drug design [2, 3]. The kinase domain adopts an active conformation with the activation loop phosphorylated at Thr474, which stabilizes the catalytically competent state. The ATP-binding pocket is relatively hydrophobic and accommodates a diverse range of small-molecule inhibitors, including the 5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][4, 5]diazepin-6-one scaffold compounds [3].

Structure-guided mutational analysis has identified key residues that are critical for kinase activity and microtubule binding. Mutations in the ATP-binding pocket (e.g., K419A) abolish catalytic activity, while mutations in the DCX domain (e.g., R89A) disrupt microtubule interactions [2]. These structure-function studies have enabled the prediction of the functional impact of cancer-associated DCLK1 mutations, distinguishing driver mutations from passenger alterations [2].

### 2.3 Post-Translational Modifications and Structural Dynamics

DCLK1 is subject to extensive post-translational modifications that modulate its structure and function:

**Phosphorylation:** DCLK1 undergoes autophosphorylation at multiple sites, including Ser329, Thr474, and Ser740. Phosphorylation of Thr474 within the activation loop is required for full kinase activity. Additionally, DCLK1 is phosphorylated by upstream kinases, including protein kinase A (PKA) and CaMKII, which integrate calcium signaling with DCLK1 function [2].

**Ubiquitination:** The E3 ubiquitin ligase KLHL15, in complex with Cullin3, targets DCLK1 for proteasomal degradation, constraining neuronal dendritogenesis [6]. This regulatory mechanism ensures precise spatiotemporal control of DCLK1 protein levels during neural development.

**Deubiquitination:** In bladder cancer, DCLK1 deubiquitinates HDAC6, stabilizing this histone deacetylase and promoting malignant progression and chemoresistance [1]. This non-canonical function of DCLK1 as a deubiquitinase expands its functional repertoire beyond kinase signaling.

### 2.4 Interactive 3D Visualization

For interactive exploration of the DCLK1 three-dimensional structure, including domain architecture, ligand-binding pockets, and mutation hotspots, please utilize the following resource:

[Interactive 3D Protein Visualizer: Load DCLK1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15075)

This visualizer enables users to rotate the protein structure, highlight specific domains, and map clinically relevant mutations onto the three-dimensional fold.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Microtubule Dynamics and Neuronal Migration

DCLK1 plays an essential role in neuronal development, where it regulates microtubule polymerization, stabilization, and retrograde transport [1, 2]. Through its DCX domain, DCLK1 binds to microtubules and promotes their polymerization, functioning redundantly with DCX itself [2]. This activity is critical for neuronal migration during cortical development, and disruption of DCLK1 function leads to impaired neuronal positioning [3].

DCLK1 also facilitates the elongation of the somatic Golgi apparatus into proximal dendrites, a process essential for polarized neuronal morphology [2]. This function requires the coordinated activity of both the DCX and kinase domains, suggesting that microtubule binding and phosphorylation signaling act in concert to regulate organelle positioning.

### 3.2 Kinase Signaling Cascades

The kinase activity of DCLK1 phosphorylates multiple substrates involved in cell survival, proliferation, and differentiation. Key signaling pathways modulated by DCLK1 include:

**Wnt/β-catenin Signaling:** DCLK1 expression in intestinal tumor stem cells activates pro-survival signaling through the Wnt pathway, promoting self-renewal and tumor propagation [4]. In Apc-mutant intestinal tumors, Dclk1+ cells exhibit enhanced β-catenin nuclear localization and transcriptional activity, driving expression of stem cell-associated genes [4, 5].

**Notch Signaling:** DCLK1 correlates with Notch pathway activation in head and neck cancer and regulates EMT through the miR-15b/DCLK1/Notch1 axis in gastric cancer [1, 6]. The kinase activity of DCLK1 appears to modulate Notch intracellular domain stability, linking DCLK1 to stem cell fate decisions.

**Hippo-YAP Pathway:** In prostate cancer, DCLK1 promotes stem cell-like properties through activation of the Hippo-YAP signaling axis [1]. DCLK1 expression leads to YAP dephosphorylation and nuclear translocation, driving transcription of YAP target genes involved in self-renewal and metastasis.

**JAK/STAT Signaling:** DCLK1 activates the JAK/STAT pathway in pancreatic cancer, where it is regulated by the transcription factor ELF1 [2]. This pathway contributes to the inflammatory tumor microenvironment and promotes cancer cell proliferation.

**NF-κB Signaling:** In macrophages, DCLK1 binds to IKKβ and induces inflammatory responses, promoting atherosclerosis [3]. This interaction enhances NF-κB activation and pro-inflammatory cytokine production, establishing DCLK1 as a mediator of chronic inflammation.

**TGF-β/Smad Signaling:** In idiopathic pulmonary fibrosis, DCLK1 promotes fibroblast activation through direct binding to Smad3, enhancing TGF-β-induced fibrotic gene expression [4].

### 3.3 Regulation of Epithelial-Mesenchymal Transition (EMT)

DCLK1 is a central regulator of the EMT program in multiple cancer types [5, 6]. DCLK1 expression induces EMT through multiple mechanisms:

1. **Transcriptional reprogramming:** DCLK1 upregulates EMT transcription factors including SNAI1, ZEB1, and TWIST1 while downregulating epithelial markers such as E-cadherin [6].
2. **Microtubule remodeling:** Through its DCX domain, DCLK1 reorganizes the microtubule cytoskeleton, facilitating the morphological changes associated with EMT [5].
3. **Extracellular vesicle reprogramming:** DCLK1 reprograms small extracellular vesicles toward a migratory phenotype in gastric cancer cells, altering their cargo to promote invasion [1].

### 3.4 Cancer Stem Cell Maintenance

DCLK1 is a well-established marker of cancer stem cells in multiple tumor types, including colorectal, pancreatic, gastric, and lung cancers [2, 3, 4]. DCLK1+ cells exhibit enhanced self-renewal capacity, tumorigenicity, and resistance to conventional therapies [4, 5]. The kinase activity of DCLK1 is required for CSC maintenance, as pharmacological inhibition or genetic knockdown of DCLK1 depletes the CSC population and inhibits tumor growth [3, 5].

In the intestine, Dclk1 marks tuft cells, a rare chemosensory epithelial lineage that functions as tumor stem cells in Apc-mutant models [3, 6]. These Dclk1+ tuft cells display quiescent stem cell-like properties and can give rise to intestinal tumors upon injury or oncogenic mutation [1, 2, 6]. The prostaglandin E2 (PGE2)/Akt signaling axis promotes stemness in Apc-mutant Dclk1+ cells, driving colitis-associated cancer [3].

### 3.5 Regulation of DNA Repair and Stress Responses

DCLK1 regulates DNA repair machinery and survival signaling pathways in response to genotoxic injury [4]. Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injury, indicating a critical role in tissue regeneration [5]. DCLK1 expression enhances the DNA damage response, promoting cell survival following chemotherapy or radiation exposure [4, 5].

### 3.6 Protein-Protein Interaction Networks

DCLK1 participates in extensive protein-protein interaction networks that mediate its diverse functions. Key interaction partners include:

- **Microtubules and tubulin:** Mediated by the DCX domain [2]
- **IKKβ:** Promotes NF-κB signaling in macrophages [3]
- **HDAC6:** Substrate for DCLK1-mediated deubiquitination [1]
- **Smad3:** Mediates TGF-β signaling in fibroblasts [4]
- **KLHL15/Cullin3:** E3 ubiquitin ligase complex that degrades DCLK1 [6]
- **Calmodulin:** Calcium-dependent regulation of kinase activity [2]

```mermaid
sequenceDiagram
    participant Ligand as "Extracellular Stimuli"
    participant Receptor as "Cell Surface Receptors"
    participant DCLK1 as "DCLK1"
    participant MT as "Microtubules"
    participant Kinase as "Downstream Kinases"
    participant TF as "Transcription Factors"
    participant CSC as "Cancer Stem Cell Phenotype"
    Ligand->>Receptor: Growth factors, cytokines, PGE2
    Receptor->>DCLK1: Activation via phosphorylation
    DCLK1->>MT: Microtubule polymerization/stabilization
    DCLK1->>Kinase: Phosphorylation of substrates (IKKβ, Smad3, HDAC6)
    Kinase->>TF: NF-κB, STAT, YAP, β-catenin activation
    TF->>CSC: EMT, self-renewal, survival gene expression
    CSC-->>DCLK1: Positive feedback via autocrine signaling
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Comprehensive genomic analyses have identified recurrent somatic mutations in DCLK1 across multiple cancer types. While DCLK1 is not among the most frequently mutated genes, specific mutations have been characterized for their functional impact on tumorigenesis [2].

**Kinase Domain Mutations:** Structure-guided analysis has identified mutations within the kinase domain that alter catalytic activity. The K419A mutation in the ATP-binding pocket abolishes kinase activity and serves as a dominant-negative tool in experimental studies [2]. Cancer-associated mutations in the activation segment (e.g., T474A) modulate kinase activity and substrate specificity, potentially contributing to oncogenic signaling [2].

**DCX Domain Mutations:** Mutations in the DCX domain, such as R89A, disrupt microtubule binding without affecting kinase activity [2]. These mutations may alter the subcellular localization of DCLK1 and its ability to regulate cytoskeletal dynamics, contributing to aberrant cell migration and invasion.

**Truncating Mutations:** Nonsense and frameshift mutations that generate C-terminally truncated proteins have been identified in various cancers. These truncations may produce dominant-negative isoforms or proteins with altered substrate specificity [2].

### 4.2 Germline Variants and Neurodevelopmental Disorders

While germline DCLK1 mutations are rare, variants in the gene have been associated with neurodevelopmental phenotypes. The X-linked intellectual disability gene product KLHL15 degrades DCLK1, and disruption of this regulatory axis leads to aberrant neuronal dendritogenesis [6]. DCLK1 variants have also been associated with variations in memory and general cognitive abilities, suggesting a role in human cognition [6].

### 4.3 Epigenetic Alterations as Clinical Biomarkers

Rather than somatic mutations, epigenetic alterations of DCLK1 are the predominant mechanism of dysregulation in cancer. Promoter hypermethylation of the α-promoter and hypomethylation of the β-promoter represent reciprocal epigenetic switches that drive isoform switching during carcinogenesis [1, 2].

**Diagnostic Applications:** DCLK1 promoter methylation in circulating free DNA serves as a prognostic biomarker in lung cancer patients [2]. Methylation levels correlate with tumor stage, treatment response, and overall survival, supporting the use of liquid biopsy-based DCLK1 methylation analysis for disease monitoring.

**Prognostic Implications:** In colorectal cancer, the expression of DCLK1-S (rather than DCLK1-L) is associated with poor prognosis and increased metastatic potential [3, 4]. Immunohistochemical detection of DCLK1-S using isoform-specific antibodies provides prognostic information beyond standard clinicopathological parameters [3].

### 4.4 DCLK1 in Non-Neoplastic Diseases

Beyond cancer, DCLK1 dysregulation contributes to several non-neoplastic diseases:

**Parkinson's Disease:** DCLK1 regulates α-synuclein levels and toxicity, and its expression is modulated by miR-150-5p in the context of chronic sleep deprivation [1, 6]. DCLK1 knockdown reduces α-synuclein accumulation and ameliorates neurotoxicity, suggesting a potential therapeutic target for PD.

**Atherosclerosis:** Macrophage DCLK1 promotes atherosclerosis by binding to IKKβ and inducing inflammatory responses [3]. DCLK1 expression in atherosclerotic plaques correlates with disease severity, and DCLK1 inhibition reduces plaque formation in mouse models.

**Idiopathic Pulmonary Fibrosis:** DCLK1 promotes fibroblast activation and fibrotic progression through Smad3 binding [4]. DCLK1 expression is elevated in IPF lung tissues, and its inhibition attenuates fibrotic remodeling.

**Hirschsprung's Disease:** DCLK1+ tuft cells are altered in Hirschsprung's disease, suggesting a role in enteric nervous system development and intestinal motility disorders [2].

### 4.5 Clinical Differentials

The differential diagnosis of DCLK1-expressing tumors requires consideration of the tissue context and isoform expression pattern:

- **Colorectal Cancer:** DCLK1-S expression distinguishes cancer stem cells from normal colonic epithelium, which expresses DCLK1-L [3, 4]
- **Pancreatic Ductal Adenocarcinoma:** DCLK1 marks quiescent pancreatic progenitor and cancer-initiating cells [4]
- **Renal Cell Carcinoma:** Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy [3]
- **Bladder Cancer:** DCLK1 drives malignant progression and chemoresistance through HDAC6 deubiquitination [1]
- **Lung Adenocarcinoma:** DCLK1 drives EGFR-TKI-acquired resistance by remodeling EMT status [5]

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

While direct interactions between viral oncoproteins and DCLK1 have not been extensively characterized, several lines of evidence suggest that DCLK1 may be modulated during viral infection and virus-associated carcinogenesis:

**Human Papillomavirus (HPV):** In head and neck squamous cell carcinoma, a subset of which is HPV-positive, DCLK1 expression correlates with Notch pathway signaling and metastatic characteristics [6]. The HPV E6/E7 oncoproteins may indirectly modulate DCLK1 expression through their effects on cellular differentiation programs and stem cell maintenance.

**Epstein-Barr Virus (EBV):** EBV infection is associated with gastric cancer, and DCLK1 is a putative cancer stem cell marker in this malignancy [1]. EBV-encoded miRNAs may target DCLK1 or its regulatory network, although specific interactions require further investigation.

### 5.2 Bacterial Effectors and the Microbiome

The intestinal microbiome influences DCLK1 expression through multiple mechanisms:

**Helicobacter pylori:** Chronic H. pylori infection is a risk factor for gastric cancer, and DCLK1 expression is upregulated in gastric cancer stem cells [1]. H. pylori virulence factors may induce DCLK1 expression through NF-κB and STAT3 signaling pathways.

**Enterotoxigenic Bacteroides fragilis (ETBF):** ETBF induces colitis and colonic tumorigenesis through activation of Wnt/β-catenin signaling [3]. Macrophage-induced bystander effects activate Wnt signaling and induce cellular dedifferentiation, potentially involving DCLK1+ cells [3].

**Gut Microbiota and Dietary Factors:** Dietary chemopreventive agents, including curcumin and honokiol, modulate DCLK1 expression through epigenetic mechanisms [4, 5, 6]. Curcumin hypomethylates the 5' promoter of DCLK1 in human colon cancer cells, restoring expression of the long isoform [5]. These dietary compounds may influence the gut microbiome, indirectly affecting DCLK1 regulation.

### 5.3 Immune Evasion Mechanisms

DCLK1 contributes to immune evasion through multiple mechanisms:

**Immunosuppressive Microenvironment:** Matrix stiffness remodels the immunosuppressive tumor microenvironment via the PIEZO1-DCLK1-STAT5B pathway in pancreatic cancer [1]. DCLK1 expression in tumor cells promotes the recruitment of immunosuppressive cells and inhibits cytotoxic T cell function.

**Tuft Cell-ILC2 Axis:** Regulatory network analysis of Dclk1 gene expression reveals a tuft cell-ILC2 axis that inhibits pancreatic tumor progression [4]. Dclk1+ tuft cells interact with type 2 innate lymphoid cells (ILC2s) to modulate the immune response, and this axis may be subverted during tumorigenesis.

**Extracellular Vesicle-Mediated Immune Modulation:** DCLK1 reprograms small extracellular vesicles toward a migratory phenotype, altering their immunomodulatory cargo [1]. These vesicles may suppress anti-tumor immunity and promote metastatic dissemination.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Small-Molecule Kinase Inhibitors

The kinase activity of DCLK1 represents an attractive therapeutic target, and several classes of small-molecule inhibitors have been developed:

**5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][4, 5]diazepin-6-one Scaffold:** Structure-activity relationship studies have identified potent DCLK1 inhibitors based on this scaffold [2, 3]. These compounds exhibit selectivity for DCLK1 over related kinases and demonstrate anti-proliferative activity in DCLK1-expressing cancer cell lines.

**LRRK2 Inhibitor Scaffolds:** Given the structural similarity between DCLK1 and LRRK2, some LRRK2 inhibitors exhibit cross-reactivity with DCLK1. These compounds may be repurposed for DCLK1-targeted therapy, although selectivity optimization is required.

**Multi-Kinase Inhibitors:** Several clinically approved multi-kinase inhibitors, including sunitinib and sorafenib, exhibit off-target activity against DCLK1. The contribution of DCLK1 inhibition to the therapeutic efficacy of these agents remains to be determined.

### 6.2 Monoclonal Antibodies

DCLK1-targeted monoclonal antibodies have demonstrated therapeutic potential against pancreatic ductal adenocarcinoma [5]. These antibodies recognize cell surface epitopes of DCLK1 and mediate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). A novel antibody against the cancer stem cell biomarker DCLK1-S is potentially useful for assessing colon cancer risk after screening colonoscopy [3].

### 6.3 microRNA-Based Therapeutics

Given the extensive regulation of DCLK1 by miRNAs, miRNA-based therapeutic strategies are being explored:

**miRNA Mimics:** Restoration of tumor-suppressive miRNAs that target DCLK1, including miR-15b, miR-137, miR-195, and let-7e, represents a promising approach [1, 4, 5, 6]. Delivery of these miRNAs using lipid nanoparticles or viral vectors could suppress DCLK1 expression and inhibit cancer stem cell maintenance.

**Anti-miRNA Oligonucleotides:** Inhibition of oncogenic miRNAs that suppress DCLK1 expression may be beneficial in specific contexts. For example, miR-150-5p downregulation in chronic sleep deprivation leads to DCLK1 upregulation in Parkinson's disease, suggesting that miR-150-5p replacement could be neuroprotective [6].

### 6.4 Epigenetic Therapies

The epigenetic regulation of DCLK1 isoforms provides opportunities for therapeutic intervention:

**DNA Methyltransferase Inhibitors:** 5-Azacitidine and decitabine, which are FDA-approved for myelodysplastic syndromes, can reverse DCLK1 α-promoter hypermethylation and restore DCLK1-L expression [1, 3, 5]. DNA hypomethylation induced by 5-aza-CdR or loss of DNMT1 inhibits colitis-associated colorectal cancer [3].

**Histone Deacetylase Inhibitors:** HDAC inhibitors, including vorinostat and romidepsin, modulate DCLK1 expression through effects on chromatin structure. In bladder cancer, DCLK1 deubiquitinates HDAC6, suggesting that HDAC6-selective inhibitors may disrupt this oncogenic axis [1].

**Histone Methyltransferase Inhibitors:** The histone methyltransferase G9a promotes mutant Kras-driven pancreatic carcinogenesis, and its deletion suppresses tumor development [4]. G9a inhibitors may indirectly modulate DCLK1 expression through effects on the epigenetic landscape.

### 6.5 Combination Strategies

DCLK1-targeted therapies are likely to be most effective in combination with conventional treatments:

**Chemosensitization:** DCLK1 inhibition enhances sensitivity to chemotherapy and radiation in colorectal cancer [5]. Combination of DCLK1 inhibitors with cisplatin or 5-fluorouracil may overcome drug resistance.

**EGFR-TKI Resistance:** DCLK1 drives EGFR-TKI-acquired resistance in lung adenocarcinoma by remodeling EMT status [5]. Combining DCLK1 inhibitors with EGFR-TKIs may prevent or overcome resistance.

**Immunotherapy:** DCLK1 modulates the immunosuppressive tumor microenvironment [1]. Combining DCLK1 inhibitors with immune checkpoint blockade may enhance anti-tumor immunity.

### 6.6 Pharmacogenomic Considerations

The pharmacogenomics of DCLK1 is an emerging field. Genetic variants in DCLK1 may influence drug response and toxicity:

- **Kinase Domain Polymorphisms:** Non-synonymous polymorphisms in the kinase domain may alter inhibitor binding affinity and therapeutic efficacy [2]
- **Promoter Variants:** Polymorphisms in the α- and β-promoters may affect isoform expression and response to epigenetic therapies [2]
- **miRNA Binding Site Variants:** Polymorphisms in the 3' UTR that disrupt miRNA binding may lead to DCLK1 overexpression and therapy resistance

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for DCLK1 research:

| Database | Accession/ID | URL |
|----------|--------------|-----|
| **NCBI Gene** | 9201 | https://www.ncbi.nlm.nih.gov/gene/9201 |
| **Ensembl** | ENSG00000133083 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133083 |
| **UniProt** | O15075 | https://www.uniprot.org/uniprotkb/O15075 |
| **RCSB PDB** | Multiple (e.g., 6B8A, 6B8B) | https://www.rcsb.org/search?q=afDCLK1 |
| **OMIM** | 604742 | https://www.omim.org/entry/604742 |
| **HGNC** | 2700 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2700 |
| **ClinVar** | Multiple | https://www.ncbi.nlm.nih.gov/clinvar/?term=DCLK1 |
| **COSMIC** | Multiple | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=DCLK1 |
| **STRING** | O15075 | https://string-db.org/network/9606.ENSP00000355785 |
| **BioGRID** | 120894 | https://thebiogrid.org/120894 |
| **PhosphoSitePlus** | O15075 | https://www.phosphosite.org/proteinAction.action?id=12683 |
| **GTEx Portal** | DCLK1 | https://gtexportal.org/home/gene/DCLK1 |
| **Human Protein Atlas** | ENSG00000133083 | https://www.proteinatlas.org/ENSG00000133083-DCLK1 |

### Gene Ontology (GO) Terms

| Category | GO Term | Accession |
|----------|---------|-----------|
| **Molecular Function** | Protein serine/threonine kinase activity | GO:0004674 |
| **Molecular Function** | Microtubule binding | GO:0008017 |
| **Molecular Function** | ATP binding | GO:0005524 |
| **Molecular Function** | Calmodulin binding | GO:0005516 |
| **Biological Process** | Microtubule polymerization | GO:0046785 |
| **Biological Process** | Neuron migration | GO:0001764 |
| **Biological Process** | Nervous system development | GO:0007399 |
| **Biological Process** | Stem cell population maintenance | GO:0019827 |
| **Biological Process** | Epithelial to mesenchymal transition | GO:0001837 |
| **Cellular Component** | Cytoplasm | GO:0005737 |
| **Cellular Component** | Microtubule | GO:0005874 |
| **Cellular Component** | Cell projection | GO:0042995 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)

## References

[1] Valenti G, Laise P, Wu F, et al. Regulatory network analysis of Dclk1 gene expression reveals a tuft cell-ILC2 axis that inhibits pancreatic tumor progression. *Cell Reports*. 2025. https://www.semanticscholar.org/paper/c3e793ad4440494bfce7926963a5a93c84c25890

[2] Zygmunt M, Hoinkis D, Hajto J, et al. Expression of alternatively spliced variants of the Dclk1 gene is regulated by psychotropic drugs. *BMC Neuroscience*. 2018. https://www.semanticscholar.org/paper/2cea5118e849edc67280431bab5290099ca220fd

[3] DCLK1 Gene. *Definitions*. 2020. https://www.semanticscholar.org/paper/dd783af2adaf1cb4736da6d9ca538fbc11b60ad8

[4] Sarkar S, O'Connell MR, Singh P. Dietary chemopreventive agent (curcumin), hypomethylates 5′ promoter of DCLK1 gene in human colon cancer cells and restores expression of long isoform of DCLK1. *Scientific Publication*. 2015. https://www.semanticscholar.org/paper/88c84c8f282be6255450c4b9be5503c2968799c0

[5] Good H, Larsen F, Shin A, et al. Prostaglandin E2 and Akt Promote Stemness in Apc Mutant Dclk1+ Cells to Give Rise to Colitis-associated Cancer. *Cellular and Molecular Gastroenterology and Hepatology*. 2025. https://www.semanticscholar.org/paper/33910f16e6faa02e375ea765daf3679a773d906c

[6] Khodadadi Kohlan A, Saidijam M, Amini R, et al. Induction of let-7e gene expression attenuates oncogenic phenotype in HCT-116 colorectal cancer cells through targeting of DCLK1 regulation. *Life Science*. 2019. https://www.semanticscholar.org/paper/4ce1cf7e8edccf3